

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Cloprostenol Formulation

Other means of identification : ESTRUMATE® (A002698)
ESTRUMATE SYNTHETIC PROSTAGLANDIN FOR CATTLE
AND HORSES (36076)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Veterinary product

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
20 Spartan Road
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Skin sensitisation, Category 1 H317: May cause an allergic skin reaction.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Warning

Hazard statements : H317 May cause an allergic skin reaction.

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Precautionary statements :

Prevention:

P272 Contaminated work clothing should not be allowed out of the workplace.

P280 Wear protective gloves.

Response:

P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Hazardous components which must be listed on the label:

Benzyl alcohol

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Benzyl alcohol	100-51-6 202-859-9 603-057-00-5	Acute Tox. 4; H302 Eye Irrit. 2; H319 Skin Sens. 1B; H317	>= 1 - < 10
Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate	55028-72-3 259-439-3	Resp. Sens. 1; H334 Repr. 1B; H360F STOT SE 1; H370 (Lungs) STOT RE 1; H372 (Ovary)	< 0,1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

- | | | |
|-------------------------|---|---|
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention if symptoms occur. |
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|--------------------------------------|
| Risks | : | May cause an allergic skin reaction. |
|-------|---|--------------------------------------|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- | | | |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
|------------------------------|---|--|

- | | | |
|--------------------------------|---|-------------|
| Unsuitable extinguishing media | : | None known. |
|--------------------------------|---|-------------|

5.2 Special hazards arising from the substance or mixture

- | | | |
|---------------------------------------|---|--|
| Specific hazards during fire-fighting | : | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides |

5.3 Advice for firefighters

- | | | |
|---|---|---|
| Special protective equipment for firefighters | : | In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment. |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. |

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.
Avoid breathing mist or vapours.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Cloprostenol Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 25312-00028 Date of last issue: 03.12.2024
 Date of first issue: 24.10.2014

Hygiene measures : Take care to prevent spills, waste and minimize release to the environment.
 : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
 Strong oxidizing agents
 Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sodium [1 α (Z),2 β (1E,3R*), 3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate	55028-72-3	TWA	0.01 ug/m ³ (OEB 5)	Internal
Further information: RSEN, Skin				
		Wipe limit	0.1 ug/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Benzyl alcohol	Workers	Inhalation	Long-term systemic effects	22 mg/m ³
	Workers	Inhalation	Acute systemic effects	110 mg/m ³
	Workers	Skin contact	Long-term systemic effects	8 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	40 mg/kg

Cloprostenol Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 25312-00028 Date of last issue: 03.12.2024
 Date of first issue: 24.10.2014

			fects	bw/day
	Consumers	Inhalation	Long-term systemic effects	5,4 mg/m ³
	Consumers	Inhalation	Acute systemic effects	27 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	4 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	20 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	4 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	20 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Benzyl alcohol	Fresh water	1 mg/l
	Marine water	0,1 mg/l
	Intermittent use/release	2,3 mg/l
	Sewage treatment plant	39 mg/l
	Fresh water sediment	5,27 mg/kg
	Marine sediment	0,527 mg/kg
	Soil	0,456 mg/kg

8.2 Exposure controls**Engineering measures**

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Organic vapour type (A)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance	:	Aqueous solution
Colour	:	clear
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	5,6 - 6,1 (20 - 25 °C)
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	1
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Molecular weight	:	No data available
Particle size	:	Not applicable

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2.000 mg/kg Method: Calculation method
---------------------	---	--

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Components:**Benzyl alcohol:**

Acute oral toxicity : LD50 (Rat): 1.200 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,4 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: The substance or mixture has no acute inhalation toxicity

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Acute oral toxicity : LD50 (Rat): > 25 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): > 50 mg/kg
Application Route: Subcutaneous

LD50 (Rat): > 50 mg/kg
Application Route: Intramuscular

LD50 (Rat): 5 mg/kg
Application Route: Intravenous
Remarks: No mortality observed at this dose.

LD50 (Mouse): 350 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 54,7 mg/kg
Application Route: Intravenous

TDLo (Monkey): 0,0025 - 0,025 mg/kg
Application Route: Intramuscular
Target Organs: Lungs
Symptoms: Diarrhoea, Vomiting, Rapid respiration

TDLo (Monkey): 0,0013 mg/kg
Application Route: Intramuscular
Target Organs: ovaries

Skin corrosion/irritation

Not classified based on available information.

Components:**Benzyl alcohol:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Remarks : Not classified due to lack of data.
Can be absorbed through skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Benzyl alcohol:**

Species : Rabbit
Method : OECD Test Guideline 405
Result : Irritation to eyes, reversing within 21 days

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Remarks : Not classified due to lack of data.

Respiratory or skin sensitisation**Skin sensitisation**

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:**Benzyl alcohol:**

Test Type : Human repeat insult patch test (HRIPT)
Exposure routes : Skin contact
Species : Humans
Result : positive

Assessment : Probability or evidence of low to moderate skin sensitisation rate in humans

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Result : Sensitiser

Germ cell mutagenicity

Not classified based on available information.

Components:**Benzyl alcohol:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Species: Mouse
 Application Route: Intraperitoneal injection
 Result: negative

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Test system: mouse lymphoma cells
 Result: negative

Test Type: Chromosomal aberration
 Test system: Human lymphocytes
 Result: equivocal

Genotoxicity in vivo : Test Type: Micronucleus test
 Species: Mouse
 Cell type: Bone marrow
 Application Route: Intraperitoneal
 Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Benzyl alcohol:

Species : Mouse
 Application Route : Ingestion
 Exposure time : 103 weeks
 Method : OECD Test Guideline 451
 Result : negative

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Remarks : Not classified due to lack of data.

Reproductive toxicity

Not classified based on available information.

Components:

Benzyl alcohol:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Result: negative
 Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Mouse

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Application Route: Ingestion
Result: negative

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Effects on fertility : Test Type: Three-generation study
Species: Rat
Application Route: Oral
General Toxicity F1: NOAEL: 0,015 mg/kg body weight
Fertility: NOAEL: > 0,04 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Species: Cattle
Application Route: Intramuscular
General Toxicity - Parent: LOAEL: 0,16 μ g/kg
Result: positive
Remarks: Abortion

Effects on foetal development : Test Type: Development
Species: Rabbit
Application Route: Subcutaneous
Teratogenicity: NOAEL: 0,250 μ g/kg
Result: No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Oral
Teratogenicity: NOAEL: 100 μ g/kg
Result: No teratogenic effects

Reproductive toxicity - Assessment : May damage fertility.

STOT - single exposure

Not classified based on available information.

Components:**Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Target Organs : Lungs
Assessment : Causes damage to organs.

STOT - repeated exposure

Not classified based on available information.

Components:**Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Target Organs : Ovary
Assessment : Causes damage to organs through prolonged or repeated exposure.

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Repeated dose toxicity**Components:****Benzyl alcohol:**

Species	: Rat
NOAEL	: 1,072 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 28 Days
Method	: OECD Test Guideline 412

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Species	: Rat
NOAEL	: 0,05 mg/kg
LOAEL	: 0,15 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Ovary

Species	: Rat
LOAEL	: 0,0125 mg/kg
Application Route	: Subcutaneous
Exposure time	: 30 Days
Target Organs	: Ovary

Species	: Monkey
NOAEL	: 0,05 mg/kg
LOAEL	: 0,15 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Heart, Testis

Aspiration toxicity

Not classified based on available information.

Components:**Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

Not applicable

Experience with human exposure**Components:****Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**

General Information	: Target Organs: Uterus (including cervix) Symptoms: Embryo-foetal toxicity, foetal mortality, menstrual irregularities, miscarriage Target Organs: Lungs Symptoms: Asthma, bronchospasm
Inhalation	: Target Organs: Lungs

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

	Symptoms: bronchospasm, Asthma
	Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.
	Target Organs: Uterus (including cervix)
	Symptoms: Embryoethal effects, menstrual irregularities
Skin contact	: Target Organs: Lungs
	Symptoms: bronchospasm
	Remarks: Can be absorbed through skin.
	Target Organs: Uterus (including cervix)
	Symptoms: Embryoethal effects

SECTION 12: Ecological information

12.1 Toxicity

Components:**Benzyl alcohol:**

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): 460 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 230 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 770 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 310 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 51 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Ecotoxicology Assessment

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

12.2 Persistence and degradability

Components:**Benzyl alcohol:**

Biodegradability	: Result: Readily biodegradable.
------------------	----------------------------------

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

Biodegradation: 92 - 96 %
Exposure time: 14 d

12.3 Bioaccumulative potential**Components:****Benzyl alcohol:**

Partition coefficient: n-octanol/water : log Pow: 1,05

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good

Cloprostenol Formulation

Version 6.1	Revision Date: 14.04.2025	SDS Number: 25312-00028	Date of last issue: 03.12.2024 Date of first issue: 24.10.2014
----------------	------------------------------	----------------------------	---

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture****The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302	: Harmful if swallowed.
H317	: May cause an allergic skin reaction.
H319	: Causes serious eye irritation.
H334	: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H360F	: May damage fertility.
H370	: Causes damage to organs.
H372	: Causes damage to organs through prolonged or repeated exposure.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Eye Irrit.	: Eye irritation
Repr.	: Reproductive toxicity
Resp. Sens.	: Respiratory sensitisation
Skin Sens.	: Skin sensitisation
STOT RE	: Specific target organ toxicity - repeated exposure
STOT SE	: Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Re-

Cloprostenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	25312-00028	Date of first issue: 24.10.2014

striction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Skin Sens. 1

H317

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN